Kymera Therapeutics, Inc.
KYMR
$24.12
$1.727.68%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.07M | 87.56M | 88.55M | 79.41M | 78.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.07M | 87.56M | 88.55M | 79.41M | 78.59M |
| Cost of Revenue | 240.25M | 221.40M | 209.11M | 195.67M | 189.08M |
| Gross Profit | -193.18M | -133.84M | -120.56M | -116.26M | -110.49M |
| SG&A Expenses | 63.53M | 61.43M | 60.09M | 56.85M | 55.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 303.78M | 282.83M | 269.20M | 252.52M | 244.12M |
| Operating Income | -256.71M | -195.27M | -180.65M | -173.11M | -165.53M |
| Income Before Tax | -223.86M | -167.47M | -157.85M | -154.59M | -146.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -223.86 | -167.47 | -157.85 | -154.59 | -146.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -223.86M | -167.47M | -157.85M | -154.59M | -146.96M |
| EBIT | -256.71M | -195.27M | -180.65M | -173.11M | -165.53M |
| EBITDA | -250.74M | -189.36M | -175.84M | -169.34M | -162.34M |
| EPS Basic | -2.97 | -2.33 | -2.41 | -2.50 | -2.52 |
| Normalized Basic EPS | -1.81 | -1.41 | -1.46 | -1.52 | -1.57 |
| EPS Diluted | -2.97 | -2.33 | -2.41 | -2.50 | -2.52 |
| Normalized Diluted EPS | -1.81 | -1.41 | -1.46 | -1.52 | -1.57 |
| Average Basic Shares Outstanding | 299.94M | 278.48M | 260.77M | 246.04M | 233.46M |
| Average Diluted Shares Outstanding | 299.94M | 278.48M | 260.77M | 246.04M | 233.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
